Eye2 logo

Subscribe to Eye²

Eye² Archives


October 22, 2014

In This Edition

Heads Up
Rochester Expands Digital Eyewear Footprint

Adlens in the Driver's Seat

Sight Seeing
FDA OK's Telescope Implant for AMD

Local Eye Site

Heads Up

Rochester Optical Expands Footprint in Fast-growing Wearables Market

Eyewear manufacturer, wholesaler and optical lab operator Rochester Optical is significantly expanding its presence in the fast-growing wearable technology market with two new partnerships.

The Rochester, N.Y.-based company announced last month that Epson America has selected it to be the recommended prescription solution provider for its Moverio BT-200 smart glasses. Rochester Optical has designed a Smart Frame for the BT-200 to carry patent-pending Smart GOLD lenses specifically optimized for this device.



New Study Shows Car Drivers' Performance With Adlens Adjustables is Comparable to Rx Eyewear

Car drivers perform at the same level whether they wear Adlens adjustable focus eyewear perform or prescription eyewear, according to a new research study conducted by Adlens and the University of Michigan Transportation Research Institute (UMTRI).

In the first of a series of studies designed to investigate driving performance while wearing adjustable focus eyewear, UMTRI researchers have found there is no statistically significant difference in hazard detection between Adlens Adjustables and prescription eyeglasses. Both were found to offer a significant advantage over wearing no corrective eyewear at all.


Sight Seeing

FDA Approves VisionCare's Telescope Implant for Macular Degeneration in Patients 65 Years and Older

VisionCare Ophthalmic Technologies, a developer of advanced visual prosthetic devices for the treatment of age-related macular degeneration (AMD), announced earlier this month that the U.S. Food and Drug Administration approved the Implantable Miniature Telescope (by Dr. Isaac Lipshitz) for use in patients living with bilateral end-stage age-related macular degeneration who are age 65 or older. The telescope implant is the only FDA approved surgical device for end-stage AMD and is Medicare eligible.


Vision Monday

Andrew Karp, Group Editor, Lenses and Technology

Send us news about new optical technologies, provide us with subjects and/or questions for a future Eye² Q&A or let us know what topics you'd like to see covered. Contact Eye²'s Editor Andrew Karp at akarp@jobson.com.

Copyright © 2014 VisionMonday. All rights reserved.
Eye² is published by Jobson Medical Information LLC,
100 Avenue of Americas, New York, NY 10013.

To subscribe to other JMI newsletters or to manage your subscription, click here.

To change your email address, reply to this email.
Write "change of address" in the subject line.
Make sure to provide us your old and new address.

To ensure delivery, please be sure to add visionmonday@jobsonmail.com to
your address book or safe senders list.

Click here if you do not want to receive future emails from Eye².